Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 20/20 | 0.71 |
| ▸ | AVPR1A | P37288 | 11/20 | 0.71 |
| ▸ | OXTR | P30559 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4138774 | 0.88 | AVPR2 (0.61) | AVPR2AVPR1AOXTR | |
| SCHEMBL5784203 | 0.87 | AVPR2 (0.69) | AVPR2AVPR1AOXTR | |
| SCHEMBL5783343 | 0.87 | AVPR2 (0.62) | AVPR2AVPR1AOXTR | |
| SCHEMBL7454551 | 0.84 | AVPR2 (0.64) | AVPR2AVPR1AOXTR | |
| SCHEMBL6068902 | 0.84 | AVPR2 (0.64) | AVPR2AVPR1AOXTR | |
| SCHEMBL4138543 | 0.83 | AVPR1A (1.00) | AVPR2AVPR1A | |
| SCHEMBL7231647 | 0.83 | AVPR2 (0.63) | AVPR2AVPR1AOXTR | |
| SCHEMBL3554268 | 0.83 | AVPR1A (0.79) | AVPR2AVPR1A | |
| SCHEMBL7223918 | 0.83 | AVPR2 (0.62) | AVPR2AVPR1AOXTR | |
| SCHEMBL6623356 | 0.83 | AVPR2 (0.65) | AVPR2AVPR1AOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227565-A1 | Biphenyl Vasopressin Agonists | WYETH (US) | 2009-09-10 | — | — | US | claimed |
| EP-1381370-B1 | N-BIPHENYLCARBONYL- AND N-PHENYLPYRIDYLCARBONYL SUBSTITUTED BI- AND TRICYCLIC AZEPINES AND DIAZEPINES AS VASOPRESSING AGONISTS | WYETH CORP (US) | 2007-03-07 | — | — | EP | claimed |
| US-6903091-B2 | Biphenyl vasopressin agonists | WYETH (US) | 2005-06-07 | — | — | US | claimed |
| US-20050075328-A1 | Biphenyl vasopressin agonists | WYETH (US) | 2005-04-07 | — | — | US | claimed |
| EP-1381370-A1 | N-BIPHENYLCARBONYL- AND N-PHENYLPYRIDYLCARBONYL SUBSTITUTED BI- AND TRICYCLIC AZEPINES AND DIAZEPINES AS VASOPRESSING AGONISTS | Wyeth (US) | 2004-01-21 | — | — | EP | claimed |
| US-20030018024-A1 | Biphenyl vasopressin agonists | WYETH | 2003-01-23 | — | — | US | claimed |
| WO-2002083145-A1 | N-BIPHENYLCARBONYL- AND N-PHENYLPYRIDYLCARBONYL SUBSTITUTED BI- AND TRICYCLIC AZEPINES AND DIAZEPINES AS VASOPRESSING AGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | claimed |
| US-20090227565-A1 | Biphenyl Vasopressin Agonists | WYETH (US) | 2009-09-10 | — | — | US | disclosed |
| US-7465722-B2 | Biphenyl vasopressin agonists | WYETH (US) | 2008-12-16 | — | — | US | disclosed |
| US-7223752-B2 | Biphenyl vasopressin agonists | WYETH (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1381370-B1 | N-BIPHENYLCARBONYL- AND N-PHENYLPYRIDYLCARBONYL SUBSTITUTED BI- AND TRICYCLIC AZEPINES AND DIAZEPINES AS VASOPRESSING AGONISTS | WYETH CORP (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20060276456-A1 | Biphenyl vasopressin agonists | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| US-6903091-B2 | Biphenyl vasopressin agonists | WYETH (US) | 2005-06-07 | — | — | US | disclosed |
| US-20050075328-A1 | Biphenyl vasopressin agonists | WYETH (US) | 2005-04-07 | — | — | US | disclosed |
| EP-1381370-A1 | N-BIPHENYLCARBONYL- AND N-PHENYLPYRIDYLCARBONYL SUBSTITUTED BI- AND TRICYCLIC AZEPINES AND DIAZEPINES AS VASOPRESSING AGONISTS | Wyeth (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20030018024-A1 | Biphenyl vasopressin agonists | WYETH | 2003-01-23 | — | — | US | disclosed |
| WO-2002083145-A1 | N-BIPHENYLCARBONYL- AND N-PHENYLPYRIDYLCARBONYL SUBSTITUTED BI- AND TRICYCLIC AZEPINES AND DIAZEPINES AS VASOPRESSING AGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227565-A1 | Biphenyl Vasopressin Agonists | AVPR2, AVPR1B, SSTR3 | AVPR2 1/4885AVPR1A 4/4885OXTR 11/4885 |
| US-20060276456-A1 | Biphenyl vasopressin agonists | AVPR2, AVPR1B, SSTR3 | AVPR2 1/4885AVPR1A 4/4885OXTR 11/4885 |
| US-20030018024-A1 | Biphenyl vasopressin agonists | AVPR2, AVPR1B, AVPR1A | AVPR2 1/4885AVPR1A 3/4885OXTR 12/4885 |
| US-20050075328-A1 | Biphenyl vasopressin agonists | AVPR2, AVPR1B, SSTR3 | AVPR2 1/4885AVPR1A 4/4885OXTR 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.